We report a 51-year-old man with an advanced malignant metastatic gastrointestinal stromal
tumour, who showed a complete response after 5 months of treatment with imatinib at a …

Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours
to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed …

Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the c-kit
receptor gene, which are targets for imatinib mesylate. However, imatinib resistance is an …

A gastrointestinal stromal tumor (GIST) is a group of mesenchymal neoplasms that have
been defined as KIT (CD117) or CD34 immunostaining-positive mesenchymal spindle cells …

Gastrointestinal stromal tumor (GIST) is a rare neoplasm exhibiting, in most cases, mutations
of c-kit. Recently it has been demonstrated that a majority of GIST patients with c-kit …

Imatinib mesylate, as treatment for gastrointestinal stromal tumors (GIST), has dramatically
changed the prognosis for survival–not only because it is efficacious, but also because it …

C-kit gene gain of function mutations are important in the pathogenesis of gastrointestinal
stromal tumors (GISTs). Imatinib is a selective tyrosine kinase inhibitor of KIT and achieves a …

The response of gastrointestinal stromal tumors (GISTs) to tyrosine kinase receptor inhibitors
(TKR-I) has been a breakthrough for small molecular therapy. We report here on the very …

Gastrointestinal stromal tumors (GISTs) developing in the colon are rare, accounting for< 5%
of all GISTs. There are few data on the clinical efficacy of tyrosine kinase inhibitors in colonic …

A 49-year-old man underwent partial resection of the jejunum for an abdominal tumor, which
was histologically confirmed to be a gastrointestinal stromal tumor (GIST) …